Brief: Vigil Neuroscience Announces First Patient Dosed In The Ignite Phase 2 Clinical Trial To Evaluate VGL101 In Patients With ALSP
14/12/2022 22:47
Dec 14 (Reuters) - Vigil Neuroscience Inc VIGL.O :
* VIGIL NEUROSCIENCE ANNOUNCES FIRST PATIENT DOSED IN THE
IGNITE
PHASE 2 CLINICAL TRIAL TO EVALUATE VGL101 IN PATIENTS WITH ALSP
Source text for Eikon: ID:nGNX25hGnF
Further company coverage: VIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vigil Neuroscience
See all newsVigil Neuroscience Inc reports results for the quarter ended June 30 - Earnings Summary
Vigil Neuroscience Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
U.S. RESEARCH ROUNDUP-Ralph Lauren, Vigil Neuroscience, Workday
Deals of the day-Mergers and acquisitions